You are here

Home » Content

An Approach to Design & Development and Evaluation of Aceclofenac Floating Pellets Using Sodium Alginate and HPMC (HPMC K4M & HPMC K100LV) as polymer

Journal Name:

  • International Journal of Innovation and Applied Studies

Publication Year:

  • 2013

Keywords (Original Language):

Author NameUniversity of Author
Bookmark/Search this post with
Abstract (Original Language): 
The present study was conducted to investigate the effect of Na‐alginate and hydroxyl propyl methyl cellulose (HPMC) polymer combination of Aceclofenac floating pellets. The Aceclofenac pellets were prepared with two different grades of HPMC polymers in the ratio of 2:1, 1:2 and 1.5:1.5 respectively while the amounts of Na‐alginate used in the formulations was 3.50, 5.25 and 7.0g. Prepared pellets were evaluated by Particle size and Morphology, Contraction ratio, Moisture content, Friability Test, Swelling study, Buoyancy time and floating time of the pellets were examined on the basis of polymer concentration. The contraction ratio of the particle was highest when pellets were prepared with 1.5% Naalginate solution and the polymer ratio was 1:2 (BX, BY, BZ). In case of Buoyancy of Pellets, When Alginate concentration was 1% and HPMC K4M & HPMC K100LV ratio was 2:1 then, the Aceclofenac pellets were not floated for long time. When the concentration of Na‐Alginate increased to 1.5%, 2%, then all pellets were floated. In case of swelling study, CY, BZ, CZ showed highest swelling of approximately 8% when Na‐alginate concentration was (1.5 % , 2%, 2 % ) and BY and CY batches showed lowest swelling of 2.9% at 4hrs when Na‐alginate concentration was 1.5 %. Friability values for each formulation were recorded in table the values of the preferred formulas are within acceptable limit. Thus, the selection and use of suitable polymers in appropriate ratio is very important in designing floating pellets of Aceclofenac.
FULL TEXT (PDF): 
PDF icon arastirmax-approach-design-development-and-evaluation-aceclofenac-floating-pellets-using-sodium-alginate-and-hpmc-hpmc-k4m-hpmc-k100lv-polymer.pdf
  • 2
447
455
  • English

REFERENCES

References: 

[1] Ballard, B.E., “An overview of prolonged action drug dosage forms: Sustained and controlled release drug delivery
systems”, Marcel Dekker, New York, pp. 1‐69, 1978.
[2] Umang Pharmatech, Chemical Applications, 2011.
[Online] Available: http://www.umangpharmatech.com/chemicalapplications/ (2013)
[3] Dooley, M., “Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease”, Drugs; 61, pp.
1351–78, 2001.
[4] Bodmeier R. and Wang J., “Microencapsulation of drugs with aqueous colloidal polymer dispersions”, J. Pharm Sci: 82,
pp. 191‐194, 1993.
[5] Prakash K., Raju PN., Shanta KK., and Lakshmi MN, “Preparation and characterization of Lamivudine microcapsules using
various cellulose polymers”, Tropical Journal of Pharmaceutical Research, 6(4), pp. 841‐847, 2007.
[6] Shrivastava A.K, Wadwa S, Ridusker D, and Mishra B, “Oral sustained delivery of Atanolol from floating matrix tablet:
Formulation and in vitro evaluation drug development”, India Pharma, 31, pp. 367‐145, 2005.
[7] Y. Murata, N. Sasaki, Miyamoto, and S Kawashima, “Use of floating Alginate gel beads for stomach specific drug
delivery”, Eur. J. Pharm. Biopharm. 50, 221, 2000.
[8] British Pharmacopoeia, “Friability of Uncoated Tablets”, Appendix XVII G, Ph. Eur. Method (2.9.7), 2011.
[9] Murata. N., Sasaki, J., Shimamaura, and S. Kawashima, “Tumor Suppressing Genes: Novel Approach”, J. Pharm. Sci.
technol. 29 (1), pp. 61‐67, 2001.
[10] Vendruscolo CW., Andreazza IF., Ganter JL., Ferrero C, and Bresolin TM, “Xanthan and galactomann matrix tablets based
for oral controlled delivery of theophylline”, International Journal of Pharmaceutics, 296, pp. 1‐11, 2005.
[11] Yeole, P.G., Galgatee, U.C., Babla I.B., and Nakhat, P.D., “Design and evaluation of xanthan gum based sustained release
matrix tablets of Diclofenac Na”, Indian J. Pharm, 2006.
[12] Banker G., Anderson R., Tablet, In : Lachman L, Liberman H, Kanig J, editors, The theory and practice of industrial
pharmacy, Philadelphia: Lea and Febiger, p. 317 , 1987.
[13] Jain SK, Rai G, Saraf DK, and Agrawal GP, “The preparation and evaluation of Albendazole microspheres for colonic
delivery”, Pharma Tech, pp. 66‐71, 2004.
[14] Ziyaur R, Kanchan K, Khar RK, Mushir A, Charoo NA, and Shamsher AA, “Characterization of 5‐fluorouracil microsphere
for colonic delivery”, AAPS Pharm Sci Tech, 7:2, 2006.

Thank you for copying data from http://www.arastirmax.com